EU MDR Vs IVDR CE Certification: Notified-Body Roles And Key Differences

EU Medical Device CE Certification CE conformity assessment for medical devices under the EU MDR or IVDR, including notified-body certification when required by device classification. This article compares how the two regulations treat classification, notified-body involvement, clinical evidence, and post-market obligations so manufacturers and suppliers can plan compliance strategies by device type.

The MDR (Medical Device Regulation) and IVDR (In Vitro Diagnostic Regulation) share a common goal—ensure safety and performance of devices in the EU—but they differ in scope, classification rules, conformity routes, and the scale of notified-body involvement. Understanding those differences is critical for manufacturers that produce both general medical devices and in vitro diagnostic devices or for organizations transitioning products from the directives to the regulations.

Classification Approach And Risk Profiles

MDR classification uses rules based on device invasiveness, duration of contact, active function, and intended use (Classes I, IIa, IIb, III). IVDR classification uses a different set of rules specific to IVDs (Classes A, B, C, D) where Class D covers highest public-health-risk assays (e.g., blood screening for transmissible agents).

Notified-Body Involvement: MDR Versus IVDR

A primary distinction is the proportion of devices that require notified-body involvement. Under the MDR, many devices—especially Class I—can be self-declared, with notified bodies required for higher-risk classes. Under the IVDR, notified-body involvement is far more common: the majority of IVDs (Classes B, C, and D) require a notified-body assessment. This has created higher demand for designated notified bodies in the IVD sector and longer timelines for IVDR conformity assessments.

Clinical Evidence And Performance Requirements

MDR requires clinical evaluation proportionate to risk and device novelty; clinical investigations may be needed for high-risk devices. IVDR raises the bar for performance evaluation and clinical evidence—manufacturers must demonstrate analytical and clinical performance, and for many Class C and D IVDs, independent performance studies or robust scientific evidence are mandatory. Notified bodies scrutinize these data thoroughly.

Quality Management Systems And Audits

Both MDR and IVDR expect a quality management system compatible with ISO 13485. Notified bodies audit QMS processes for higher-risk products. The IVDR has led to an increased frequency of QMS audits for IVD manufacturers because more devices fall into notified-body scopes.

Conformity Assessment Routes And Annexes

MDR conformity routes reference several annexes (e.g., Annex IX, Annex XI) covering full quality assurance, type-examination, and design dossier assessments. IVDR has its own annex pathways with stricter requirements for performance evaluation and batch-release procedures for certain IVDs. Manufacturers must identify which annex-based route applies to their device and plan timelines accordingly.

Notified-Body Capacity And Market Impact

Because IVDR places more devices under notified-body oversight, the notified-body bottleneck is a greater concern for IVD makers. Manufacturers should verify notified-body designation for specific scopes and confirm their capacity to accept new clients—this can materially affect launch timing.

Post-Market Surveillance, Vigilance, And EUDAMED

Both regulations strengthen post-market surveillance (PMS) and clinical/ performance follow-up requirements. Reporting obligations, periodic safety update reports (PSURs for MDR) or periodic safety performance reports (PSPRs under IVDR), and vigilance timelines are more prescriptive. The EU's EUDAMED database will centralize many records such as vigilance reports, market surveillance data, and UDI registration—though national roll-out timelines vary.

Practical Consequences For Manufacturers

• Resource Planning: IVDR requires more evidence and notified-body work; expect higher costs and longer schedules than many MDR conformity routes.
• Data Strategy: For IVDR, strong analytical and clinical performance data are non-negotiable; plan studies early and align with notified-body expectations.
• Notified-Body Selection: Confirm notified-body scope for MDR/IVDR separately; expertise in IVDs vs implantable devices differs across bodies.

Example Comparison

An MDR Class IIa infusion pump will need technical documentation, a QMS audit, and likely a notified-body review of design and clinical data. An IVDR Class C molecular diagnostic assay for pathogen detection will require a notified-body performance evaluation, analytical/clinical study evidence, and robust manufacturing controls—often more intensive evidence than comparable MDR devices.

In short, the EU Medical Device CE Certification obligations under MDR and IVDR share common compliance pillars—QMS, technical documentation, and post-market systems—but the IVDR generally demands broader notified-body involvement and stronger performance evidence, particularly for higher-risk IVDs. Manufacturers must map classification, evidence needs, and notified-body availability when planning EU market entry.